Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG) Versus Alectinib (ALECENSA) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI)

Next Previous
Trial Profile

A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG) Versus Alectinib (ALECENSA) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brigatinib (Primary) ; Alectinib
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ALTA-3
  • Sponsors ARIAD Pharmaceuticals; Takeda; Takeda Development Center Americas

Most Recent Events

  • 24 Sep 2024 Status changed from active, no longer recruiting to completed.
  • 21 Aug 2024 Planned End Date changed from 30 Aug 2024 to 30 Sep 2024.
  • 14 Aug 2024 Planned End Date changed from 30 Sep 2024 to 30 Aug 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top